Vistagen Therapeutics VTGN

Vistagen Therapeutics, Inc. is a late stage biopharmaceutical company focused on discovering and developing non systemic intranasal product candidates known as pherines that target nose to brain neurocircuitry. The company’s pipeline includes five clinical stage pherine candidates: fasedienol for social anxiety disorder, itruvone for major depressive disorder, PH80 for menopausal hot flashes and premenstrual dysphoric disorder, PH15 for mental fatigue related cognitive and psychomotor impairment, and PH284 for cancer cachexia.

Vistagen Therapeutics, Inc. has not yet commercialized any product and therefore does not generate product sales revenue. Revenue to date comes from licensing and collaboration agreements, including an upfront payment of five million dollars and potential milestone payments of up to one hundred seventy two million dollars from AffaMed Therapeutics for fasedienol, and a one point five million dollar payment from Fuji Pharma for exclusive negotiation rights to PH80 in Japan.

Vistagen Therapeutics, Inc. positions itself as a pioneer in non systemic intranasal therapies that act via nose to brain neurocircuitry, offering a mechanism distinct from existing oral and systemic treatments. The company claims that fasedienol could become the first FDA approved acute treatment for social anxiety disorder, a market where no such therapy currently exists. Competitors in the anxiety and depression space include larger firms such as Neuphoria, Vanda Pharmaceuticals, PureTech, Axsome Therapeutics, Relmada Therapeutics, Johnson & Johnson and others developing alternative therapies. For menopausal vasomotor symptoms, the company faces competition from hormone therapies, Veozah marketed by Astellas Pharma and the investigational elinzanetant from Bayer. Vistagen emphasizes its potential advantages of rapid onset, reduced risk of side effects, abuse liability and drug interactions due to its non systemic approach.

Vistagen Therapeutics, Inc. intends to serve patients suffering from social anxiety disorder, major depressive disorder, menopausal hot flashes, premenstrual dysphoric disorder, mental fatigue and cancer cachexia. Its future customers will include healthcare providers, hospitals, clinics and pharmacies that will dispense its intranasal therapies upon regulatory approval.